LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Recruiting

Phase 2

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Sponsor:

Lutris Pharma Ltd.

Code:

NCT04759664

Conditions

EGFRI Induced Acneiform Lesions

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LUT014 Gel (Dose 1)

LUT014 Gel (Dose 2)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Lutris Pharma Ltd. on 2023-10-06.